• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, July 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Researchers identify target for shutting down growth of prostate cancer cells

Bioengineer by Bioengineer
March 6, 2014
in Cancer
Reading Time: 2 mins read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Scientists at UT Southwestern Medical Center have identified an important step toward potentially shutting down the growth of prostate cancer cells.

Researchers identify target for shutting down growth of prostate cancer cells

Dr. Ralf Kittler, Assistant Professor of Pharmacology at UT Southwestern.

Dr. Ralf Kittler, Assistant Professor of Pharmacology, studies ERG, a protein that facilitates the transformation of normal prostate cells into cancer cells. His lab found that an enzyme called USP9X protects ERG from degradation and subsequently found that a molecule called WP1130 can block USP9X and lead to the destruction of ERG.

“We now have a target that we could potentially exploit to develop a drug for treatment,” said Dr. Kittler, UT Southwestern’s first Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research.

The findings are published in the Proceedings of the National Academy of Sciences. Dr. Kittler’s team tested the molecule successfully in mice, but the process needs to be improved to be effective in humans, he said. Toxicity and side effects also will be tested, so much work lies ahead, and it could take many years before knowing whether the molecule can be developed into a drug that is effective in humans.

“It’s a good start, and now we are in a position to develop the finding further in an effort to move into the clinic,” said Dr. Kittler, the John L. Roach Scholar in Biomedical Research of UT Southwestern’s Endowed Scholars Program.

The observation may represent an important advance against one of the major cancer killers. Prostate cancer is the most common type of cancer in men and the second most common cause of male cancer death in the United States. The disease caused nearly 30,000 deaths in 2013, according to the American Cancer Society.

Metastatic prostate cancer currently is treated with drugs that inhibit a protein called Androgen Receptor. This treatment initially halts cancer growth, but eventually the cancer becomes resistant to the drugs. Dr. Kittler’s findings offer a new avenue of research.

Dr. Kittler’s research was supported by CPRIT. Other UT Southwestern researchers involved include Dr. Payal Kapur, Associate Professor of Pathology and Urology; Dr. Yair Lotan, Professor of Urology; Dr. Ganesh Raj, Associate Professor of Urology; and Dr. Jer-Tsong Hsieh, Professor of Urology.

Story Source:

The above story is based on materials provided by The University of Texas Southwestern Medical Center, Patrick McGee.

Share12Tweet8Share2ShareShareShare2

Related Posts

Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel

July 18, 2026

KPNA2 overexpression worsens T4 colorectal cancer prognosis by nuclear c-Myc suppression of p21

July 17, 2026

Blood DNA test better selects patients for prostate cancer radiopharmaceutical therapy

July 17, 2026

IRP1/ARID3A complex identified as a new epigenetic driver of pancreatic cancer chemoresistance

July 17, 2026
Please login to join discussion

POPULAR NEWS

  • A painless adhesive

    49 shares
    Share 20 Tweet 12
  • Groundbreaking Discovery: New Shark Species Identified for the First Time

    34 shares
    Share 14 Tweet 9
  • 研究人员开发认知工具包,实现阿尔茨海默症早期检测

    50 shares
    Share 20 Tweet 13
  • A varied menu

    51 shares
    Share 22 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Factors Influencing Elderly Preference for Dental Services

Frequency-Dependent Deep Brain Stimulation in Motor Thalamus Alters Speech and Swallowing

Neonatal Monocyte Iron Handling Drives Immunometabolic Responses in Sepsis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.